Loading clinical trials...
Loading clinical trials...
Ancillary Observational Study of Post-Frontline Sequential Treatment of Adult Philadelphia Chromosome-Positive (Ph+) Acute Lymphoblastic Leukemia (ALL) Patients With Dasatinib and the Bispecific Monoclonal Antibody Blinatumomab
Conditions
Interventions
Dasatinib and blinatumomab
Locations
17
Italy
Aou Consorziale Policlinico - Bari - Uo Ematologia Con Trapianto
Bari, Italy
Asst Papa Giovanni Xxiii - Ospedale Di Bergamo - Sc Ematologia
Bergamo, Italy
Asst Degli Spedali Civili Di Brescia - Uo Ematologia
Brescia, Italy
Ctc U.O Di Ematologia Con Trapianto Di Midollo Osseo - Catania
Catania, Italy
Aou Careggi - Firenze - Sod Ematologia
Florence, Italy
Asl Lecce, Ospedale 'V. Fazzi' - Uo Ematologia
Lecce, Italy
Start Date
May 10, 2019
Primary Completion Date
May 1, 2024
Completion Date
May 1, 2024
Last Updated
October 12, 2022
NCT05376111
NCT04065399
NCT07295951
NCT05453500
NCT05442515
NCT05292664
Lead Sponsor
Gruppo Italiano Malattie EMatologiche dell'Adulto
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions